Glen Evans has lived the inventor’s dream. He came up with a brilliant idea, founded a biotech start-up called Egea Biosciences, Inc., and then sold it to Johnson & Johnson in 2004 for millions of dollars.

“One could say that Egea was really built upon [a] patent,” says Evans, 53. Getting that patent, however, was far from easy. When he first met with McDermott Will & Emery counsel David Gay in 2001, Evans had what he calls “a messy case.” “[Evans] needed help and was sophisticated enough to know he needed help,” says Gay, who was introduced to Evans by a venture capitalist who had invested in Egea.

This content has been archived. It is available through our partners, LexisNexis® and Bloomberg Law.

To view this content, please continue to their sites.

Not a Lexis Subscriber?
Subscribe Now

Not a Bloomberg Law Subscriber?
Subscribe Now

Why am I seeing this?

LexisNexis® and Bloomberg Law are third party online distributors of the broad collection of current and archived versions of ALM's legal news publications. LexisNexis® and Bloomberg Law customers are able to access and use ALM's content, including content from the National Law Journal, The American Lawyer, Legaltech News, The New York Law Journal, and Corporate Counsel, as well as other sources of legal information.

For questions call 1-877-256-2472 or contact us at [email protected]